


イプリフラボン（日本薬局方記載条件）  
Ipriflavone (The Japanese Pharmacopoeia)


F170222A

(A) Assay : Standard solution\*


(60 µg/mL Ipriflavone, 1 µL/mL Di-*n*-butyl phthalate)



|  | System suitability requirement | Result |
|--|--------------------------------|--------|
| Resolution (1, 2)  | ≥ 3                            | 10.5   |
| Relative standard deviation of the peak area ratio of 1 to 2 (n=6) | ≤ 1.0%                         | 0.15%  |




Ipriflavone



Di-*n*-butyl phthalate (I.S.)

(B) Related substance : Standard solution\*

(0.6 µg/mL Ipriflavone)



|   | System suitability requirement | Result |
|---|--------------------------------|--------|
| Theoretical plate number (Ipriflavone)  | ≥ 2,000                        | 4,700  |
| Tailing factor (Ipriflavone)  | ≤ 1.5                          | 0.88   |
| Relative standard deviation of the peak area (n=6) (Ipriflavone)  | ≤ 2.0%                         | 1.31   |
| Peak area ratio of test solution for required detectability (0.06 µg/mL) to standard solution (Ipriflavone) | 7-13%                          | 9.9%   |

Column : YMC-Triart C8 (5 µm, 12 nm)  
150 X 4.0 mm I.D.

Eluent : acetonitrile/water (60/40)

Flow rate : 1.0 mL/min (*adjust the flow rate so that the retention time of Ipriflavone is about 6 min*)

Temperature : 25°C

Detection : UV at 280 nm

Injection : 20 µL

(The Japanese Pharmacopoeia 17th; Assay, Related substances)

\* All standard solutions were prepared from Ipriflavone supplied as a reagent for laboratory use.